MUMU
MCID: FLR002
MIFTS: 57

Filariasis (MUMU)

Categories: Immune diseases, Infectious diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Filariasis

MalaCards integrated aliases for Filariasis:

Name: Filariasis 11 58 75 53 43 14 71 31 33
Disease Due to Superfamily Filarioidea 11
Bancroftian Filarial Fever 33
Bancroftian Filariasis 33
Malayan Filariasis 33
Wuchereriosis 33
Brugiosis 33
Wanganga 33
Mumu 33

Characteristics:


Prevelance:

>1/1000 (Specific population) 58

Age Of Onset:

All ages 58

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 11 DOID:1080
ICD9CM 34 125.9
MeSH 43 D005368
NCIt 49 C34611
SNOMED-CT 68 50342004
MESH via Orphanet 44 D005368
ICD10 via Orphanet 32 B74.0 B74.1 B74.2 more
UMLS via Orphanet 72 C0016085
Orphanet 58 ORPHA2034
UMLS 71 C0016085

Summaries for Filariasis

Orphanet: 58 A parasitic disease caused by tissue-invasive, vector-borne nematodes which can be found anywhere in the human body and that are transmitted to humans through the bite of an infected mosquito or fly or by consumption of unsafe drinking water and which, depending on the subtype can manifest with lymphedema, dermatitis, subcutaneous edema and eye involvement. The disorder is a major public health problem in many tropical and subtropical countries. Six subtypes have been described in the literature: lymphatic filariasis, onchocerciasis, loiasis, mansonelliasis, dirofilariasis and dracunculiasis caused by Wuchereria bancrofti and filarioidea of the genus Brugia; Onchocerca volvulus; Loa loa; Mansonella; Dirofilaria; and Dracunculus medinensis, respectively. Tropical eosinophilia is considered a frequent manifestation.

MalaCards based summary: Filariasis, also known as disease due to superfamily filarioidea, is related to filarial elephantiasis and onchocerciasis. An important gene associated with Filariasis is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and Disease. The drugs Doxycycline and Artenimol have been mentioned in the context of this disorder. Affiliated tissues include eye, lymph node and breast, and related phenotypes are homeostasis/metabolism and immune system

Disease Ontology: 11 A parasitic helminthiasis infectious disease that involves parasitic infection of the lymphatics and subcutaneous tissue by nematodes of the superfamily Filarioidea.

Wikipedia: 75 Filariasis is a parasitic disease caused by an infection with roundworms of the Filarioidea type. These... more...

Related Diseases for Filariasis

Diseases related to Filariasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 865)
# Related Disease Score Top Affiliating Genes
1 filarial elephantiasis 33.2 TNF TLR4 TLR2 IL5 IL2 IL10
2 onchocerciasis 32.6 IL5 IL2 IGHE
3 hypereosinophilic syndrome 31.4 IL5 IL2 IL10 IGHE IFNG
4 ascaris lumbricoides infection 31.2 IL5 IL10 ALB
5 dengue disease 30.9 TNF IL7 IL6 IL10 ALB
6 strongyloidiasis 30.7 IL5 IL10 IGHE IFNG
7 schistosomiasis 30.7 TNF IL5 IL2 IL10 IGHE IFNG
8 urinary schistosomiasis 30.7 IL5 IL10 IGHE
9 lymphadenitis 30.7 TNF TLR9 TLR4 PDCD1 IL6 IL10
10 orchitis 30.6 TNF IL6 IL2 IL10
11 endomyocardial fibrosis 30.6 TNF IL5 IL10
12 encephalitis 30.6 TNF TLR2 NOS2 IL6 IL10
13 parasitic helminthiasis infectious disease 30.5 TNF TLR4 TLR2 IL6 IL5 IL2
14 toxocariasis 30.4 IL6 IL5 IL10 IGHE
15 glomerulonephritis 30.4 TNF TLR9 NOS2 IL6 IL10 ALB
16 sleeping sickness 30.3 TNF IL10 ALB
17 cellulitis 30.3 TNF IL6 IL5 ALB
18 trypanosomiasis 30.3 TNF TLR2 IL6 IL2 IL10 IFNG
19 lymphangioma 30.3 TNF IL6 IL10 IFNG
20 cysticercosis 30.3 TLR4 IL6 IL5 IL10 IGHE
21 clonorchiasis 30.3 TNF IL2 IL10 IGHE IFNG
22 human immunodeficiency virus type 1 30.3 IL7 IL2 IL10 IFNG
23 trachoma 30.3 TNF IL6 IL10
24 ige responsiveness, atopic 30.2 IL5 IL10 IGHE IFNG
25 intestinal schistosomiasis 30.2 TNF IL5 IL2 IL10
26 serum amyloid a amyloidosis 30.2 TNF IL6 ALB
27 pericarditis 30.2 TNF IL6 IFNG
28 ebola hemorrhagic fever 30.2 TNF IL6 IL2 IL10
29 trichinosis 30.2 TNF IL6 IL5 IL10
30 scrub typhus 30.2 TNF TLR4 TLR2 IL10 IFNG
31 allergic disease 30.2 TNF IL6 IL5 IL2 IL10 IGHE
32 angioedema 30.2 IL6 IL5 IL2 IL10 IGHE
33 urticaria 30.2 TNF IL6 IL5 IL10 IGHE IFNG
34 pericardial effusion 30.1 TNF IL6 ALB
35 dengue hemorrhagic fever 30.1 TNF IL6 IL10 ALB
36 choroiditis 30.1 TNF IL10 IFNG
37 nephrotic syndrome 30.1 TNF IL6 IL2 EDN1 CTLA4 ALB
38 echinococcosis 30.1 TNF TLR4 TLR2 IL6 IL5 IL10
39 actinomycosis 30.1 TNF IL10 ALB
40 trichomoniasis 30.1 TNF IL6 IL10
41 iridocyclitis 30.1 TNF IL6 IL10
42 fascioliasis 30.0 IL10 IFNG ALB
43 babesiosis 30.0 TNF IL10 ALB
44 viral encephalitis 30.0 TNF IL6 IL10
45 typhoid fever 30.0 TNF TLR4 IL6 IFNG ALB
46 vasculitis 30.0 TNF IL6 IL10 CTLA4
47 uveitis 30.0 TNF IL6 IL2 IL10 IFNG CTLA4
48 mucocutaneous leishmaniasis 30.0 TNF IL5 IL2 IL10
49 syphilis 30.0 TNF TLR2 IGHE ALB
50 rheumatic heart disease 30.0 TNF TLR2 IL6 IL10

Graphical network of the top 20 diseases related to Filariasis:



Diseases related to Filariasis

Symptoms & Phenotypes for Filariasis

MGI Mouse Phenotypes related to Filariasis:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 ALB CTLA4 EDN1 GATA3 IFNG IL10
2 immune system MP:0005387 10.3 ALB CHIT1 CTLA4 GATA3 IFNG IGHE
3 neoplasm MP:0002006 10.29 ALB IFNG IL10 IL2 IL5 IL6
4 digestive/alimentary MP:0005381 10.28 ALB CTLA4 EDN1 GATA3 IFNG IL10
5 liver/biliary system MP:0005370 10.27 ALB CTLA4 IFNG IL10 IL2 IL5
6 endocrine/exocrine gland MP:0005379 10.27 ALB CTLA4 EDN1 GATA3 IFNG IL10
7 muscle MP:0005369 10.25 ALB EDN1 GATA3 IFNG IL10 IL6
8 renal/urinary system MP:0005367 10.22 ALB EDN1 GATA3 IFNG IL6 NOS2
9 cellular MP:0005384 10.18 ALB GATA3 IFNG IL10 IL2 IL6
10 cardiovascular system MP:0005385 10.18 ALB CTLA4 EDN1 GATA3 IFNG IL10
11 no phenotypic analysis MP:0003012 10.08 GATA3 IFNG IGHE IL10 IL2 IL7
12 respiratory system MP:0005388 10 CTLA4 IFNG IL10 IL2 IL5 IL6
13 skeleton MP:0005390 9.9 CTLA4 EDN1 GATA3 IFNG IL10 IL6
14 hematopoietic system MP:0005397 9.89 CTLA4 GATA3 IFNG IGHE IL10 IL2
15 mortality/aging MP:0010768 9.47 ALB CTLA4 EDN1 GATA3 IFNG IL10

Drugs & Therapeutics for Filariasis

Drugs for Filariasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
2
Artenimol Approved, Experimental, Investigational Phase 3 71939-50-9 540327
3
Piperaquine Approved, Experimental, Investigational Phase 3 4085-31-8
4
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
5
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 3 90-89-1 3052
6
Moxidectin Approved, Investigational, Vet_approved Phase 3 113507-06-5 72728820
7
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
8 Antimalarials Phase 3
9 Citrate Phase 3
10
Praziquantel Approved, Investigational, Vet_approved Phase 1 55268-74-1 4891
11
Benzimidazole Experimental, Investigational Phase 1 51-17-2 5798
12
Oxfendazole Investigational, Vet_approved Phase 1 53716-50-0 40854
13
Emodepside Investigational, Vet_approved Phase 1 155030-63-0
14 Pharmaceutical Solutions Phase 1
15 Toltrazuril Phase 1
16
Mebendazole Approved, Vet_approved 31431-39-7 4030
17
Piperazine Approved, Vet_approved 110-85-0 4837
18
Permethrin Approved, Investigational 52645-53-1 40326
19 Calcium, Dietary
20 Anticoagulants
21 Piperazine citrate
22 DMP 777 157341-41-8
23 Chelating Agents
24 Liver Extracts
25
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 Impact of Albendazole -Ivermectin Combination Treatment on Wuchereria Bancrofti Infection and Transmission in Mali Completed NCT02784743 Phase 4 ''albendazole'' and ''ivermectin''
2 Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations Completed NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
3 Safety of the Co-administration of Azithromycin, Albendazole and Ivermectin Versus Standard Treatment Regimens During Mass Drug Administration (MDA) in Ethiopia: a Cluster-randomized Trial Completed NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
4 AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
5 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Completed NCT02927496 Phase 3 Doxycycline;Placebo
6 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Completed NCT02929134 Phase 3 Doxycycline;Placebo
7 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Completed NCT02929121 Phase 3 Doxycycline;Placebo
8 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
9 A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
10 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) DeWorm3 Project Recruiting NCT03014167 Phase 3 Albendazole
11 Adjunctive Ivermectin Mass Drug Administration for Malaria Control on the Bijagos Archipelago of Guinea Bissau: A Cluster-randomized Placebo-controlled Trial Recruiting NCT04844905 Phase 3 Ivermectin;Placebo;Dihydroartemisinin-piperaquine
12 A Clinical Trial to Assess the Safety and Efficacy of Moxidectin Combination Treatments vs. Ivermectin Combination Treatments for Bancroftian Filariasis Active, not recruiting NCT04410406 Phase 3 Ivermectin;Diethylcarbamazine;Albendazole;Moxidectin
13 Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline Completed NCT00340691 Phase 2 Doxycycline
14 Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa Completed NCT01975441 Phase 2 Diethylcarbamazine;Albendazole;Ivermectin
15 Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00511004 Phase 2 Albendazole;Diethylcarbamazine
16 Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00375583 Phase 2 DEC/Albendazole
17 A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03664063 Phase 2 Azithromycin;Albendazole;Ivermectin;Diethylcarbamazine
18 Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study Completed NCT00339417 Phase 2 Albendazole;Ivermectin
19 A Phase 1, Bioavailability Study to Investigate the Pharmacokinetics, Safety and Tolerability of an Oxfendazole Tablet Formulation in a Randomized, Double-Blind, Placebo-Controlled Design After Single and Multiple Oral Dosing in Healthy Adult Volunteers Completed NCT04920292 Phase 1 Oxfendazole;Placebo
20 A Phase 1, Single-Blind, Randomized, Placebo Controlled, Parallel-Group, Multiple-Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT03383614 Phase 1 LSF emodepside (BAY 44-4400) or matching placebo
21 Phase1,Randomized,Open-Label,Parallel-Group,Relative Bioavailability Study to Investigate PK,Including Food Effect,Safety and Tolerability of Single Doses of New Immediate Release Tablet Formulations of Emodepside (BAY 44-4400),Compared to Oral Solution,in Healthy Male Subjects Completed NCT03383523 Phase 1 Emodepside (BAY 44-4400)
22 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire Completed NCT02845713 Phase 1 Ivermectin, Diethylcarbamazine Albendazole (IDA)
23 Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug Not yet recruiting NCT05084560 Phase 1 AWZ1066S;Placebo
24 Spontaneous Antigenemia in Loiasis, A Study of the Loiasis Antigens Responsible for Cross-reactivity in the Rapid Diagnostic Test for Lymphatic Filariasis Unknown status NCT04258670
25 Prevalence Survey for Innovative and Intensified Disease Management (IDM) Neglected Tropical Diseases (NTDs): A Cluster Randomised Two-stage Active Case Search for IDM-NTDs in Liberia Unknown status NCT03683745
26 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia Completed NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
27 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole (annual);Diethylcarbamazine (annual);Albendazole (semiannual);Diethylcarbamazine (semiannual)
28 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
29 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
30 Community Studies to Monitor the Impact of Triple Drug Therapy Relative to Double Drug Therapy on Lymphatic Filariasis Infection Indicators Completed NCT03352206 2 drug dose - DA;3 drug dose - IDA
31 Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire] Completed NCT02974049 Albendazole;Ivermectin;Diethylcarbamazine
32 Research for Elimination of Human Filariasis Completed NCT00145223
33 Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis Completed NCT00139100 antimicrobial agent in soap
34 Exhaled NO Testing in Filariasis Completed NCT01628497
35 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
36 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
37 Studies on the Interaction Between HIV Infection, Lymphatic Filariasis and Diethylcarbamazine Completed NCT00295698 Diethylcarbamazine
38 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis: Monitoring Efficacy of Ongoing Treatment Programs in Papua New Guinea Completed NCT03268252
39 A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali Completed NCT01586169 triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
40 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis Completed NCT02899936 3 drug dose - IDA;2 drug dose - DA
41 Coinfection With Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications Completed NCT00471666
42 Effect of Filarial Infection on Antigen-Specific Immune Responses in Latent Tuberculosis Completed NCT01547884
43 Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas Completed NCT03131401
44 Changes in HIV Viral Load in Patients Undergoing Treatment for Filarial Infection Completed NCT00344279
45 When is it Appropriate to Stop? Applied Field Research to Develop an M&E Strategy to Recruiting NCT04124250
46 Host Response to Infection and Treatment in the Filarial Diseases of Humans Recruiting NCT00001230
47 Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi, Open Label Study Terminated NCT01213576 Albendazole 400mg and ivermectin 200mcg/kg;Albendazole and ivermectin;albendazole 800mg and ivermectin 400mcg/kg bi-annually

Search NIH Clinical Center for Filariasis

Cochrane evidence based reviews: filariasis

Genetic Tests for Filariasis

Anatomical Context for Filariasis

Organs/tissues related to Filariasis:

MalaCards : Eye, Lymph Node, Breast, Liver, T Cells, Skin, Bone Marrow

Publications for Filariasis

Articles related to Filariasis:

(show top 50) (show all 6967)
# Title Authors PMID Year
1
Protective immunity in human filariasis: a role for parasite-specific IgA responses. 53 62
18588480 2008
2
Chitotriosidase deficiency is not associated with human hookworm infection in a Papua New Guinean population. 53 62
17765019 2007
3
IgE memory: persistence of antigen-specific IgE responses years after treatment of human filarial infections. 53 62
16630955 2006
4
Interleukin-10 (IL-10) counterregulates IL-4-dependent effector mechanisms in Murine Filariasis. 53 62
15501755 2004
5
Polymorphisms of innate immunity genes and susceptibility to lymphatic filariasis. 53 62
14551607 2003
6
A four year follow up study of filaria specific IgE response in individuals with hydrocele. 53 62
11247197 2000
7
IL-5 is essential for vaccine-induced protection and for resolution of primary infection in murine filariasis. 53 62
11138639 2000
8
Antigen-stimulated IL-4, IL-13 and IFN-gamma production by human T cells at a single-cell level. 53 62
9808184 1998
9
Differential decline in filaria-specific IgG1, IgG4, and IgE antibodies in Brugia malayi-infected patients after diethylcarbamazine chemotherapy. 53 62
7594718 1995
10
Differential antibody isotype reactivity to specific antigens in human lymphatic filariasis: gp15/400 preferentially induces immunoglobulin E (IgE), IgG4, and IgG2. 53 62
7558279 1995
11
Differential expression of IgE and IgG4 specific antibody responses in asymptomatic and chronic human filariasis. 53 62
8473742 1993
12
Cytokine regulation of antigen-driven immunoglobulin production in filarial parasite infections in humans. 53 62
2112154 1990
13
First Report of Sarconema eurycerca Heart Infection in Mute Swans in Serbia. 62
36107330 2022
14
Effects of blood meal sources on the biological characteristics of Aedes aegypti and Culex pipiens (Diptera: Culicidae). 62
36187452 2022
15
Visualization of the Linear and Spatial Organization of Chromosomes in Mosquitoes. 62
35960626 2022
16
Disseminated histoplasmosis in a patient with chronic lymphoedema. 62
36193195 2022
17
Immunomodulatory effects of chitosan nanoparticles as vaccine delivery agent against lymphatic filariasis through mucosal immunization. 62
36220408 2022
18
Correction: Multi-drug resistant bacteria isolates from lymphatic filariasis patients in the Ahanta West District, Ghana. 62
36324092 2022
19
No evidence of lymphatic filariasis transmission in Bamako urban setting after three mass drug administration rounds. 62
36066741 2022
20
Prevalence and risk factors for blood filariasis among HIV-infected adults in Gabon, Central Africa: a pilot study. 62
35474144 2022
21
Correction: India can consider integration of three eliminable disease control programmes on malaria, lymphatic filariasis, and visceral leishmaniasis. 62
36409694 2022
22
Comparative evaluation of different versions of exposure-free mosquito electrocuting traps and barrier screen trap for monitoring outdoor densities and biting time phenotypes by malaria and filariasis vectors in Tanzania. 62
36369172 2022
23
Correction to: No evidence of lymphatic filariasis transmission in Bamako urban setting after three mass drug administration rounds. 62
36355182 2022
24
Assessment of factors related to individuals who were never treated during mass drug administration for lymphatic filariasis in Ambon City, Indonesia. 62
36367853 2022
25
Filariasis in an alcoholic male-coincidental or causal association? 62
36318173 2022
26
Knowledge, attitude, and practice regarding mosquito-borne diseases among migrant laborers from a migrant settlement in Ponekkara, Ernakulam Kerala. 62
36412475 2022
27
Evaluating and mitigating the potential indirect effect of COVID-19 on control programmes for seven neglected tropical diseases: a modelling study. 62
36240827 2022
28
Antifilarial efficacy of andrographolide: Ex vivo studies on bovine filarial parasite Setaria cervi. 62
35985449 2022
29
The microbial community associated with Parascaris spp. infecting juvenile horses. 62
36333754 2022
30
An overview of human helminthioses in Vietnam: Their prevention, control and lessons learnt. 62
36375522 2022
31
A large case series of travel-related Mansonella perstans (vector-borne filarial nematode): a TropNet study in Europe. 62
35417002 2022
32
Integrated xenosurveillance of Loa loa, Wuchereria bancrofti, Mansonella perstans and Plasmodium falciparum using mosquito carcasses and faeces: A pilot study in Cameroon. 62
36322515 2022
33
RNAi-mediated knockdown of arginine kinase genes leads to high mortality and negatively affect reproduction and blood-feeding behavior of Culex pipiens pallens. 62
36413567 2022
34
Novel Genome Sequences and Evolutionary Dynamics of the North American Anopheline Species Anopheles freeborni, crucians, quadrimaculatus, and albimanus. 62
36377778 2022
35
Communication in Neglected Tropical Diseases' elimination: A scoping review and call for action. 62
36228006 2022
36
Diethylcarbamazine mediated potentiation of emodepside induced paralysis requires TRP-2 in adult Brugia malayi. 62
36368250 2022
37
Mosquito Vectors (Diptera: Culicidae) and Mosquito-Borne Diseases in North Africa. 62
36292910 2022
38
Characterization of the genetics and epidemiology of Brugia sp. in domestic dogs in Chad, Africa. 62
36184112 2022
39
Nanopore Sequencing Using the Full-Length 16S rRNA Gene for Detection of Blood-Borne Bacteria in Dogs Reveals a Novel Species of Hemotropic Mycoplasma. 62
36250862 2022
40
Modulation of immunological responses by aqueous extract of Datura stramonium L. seeds on cyclophosphamide-induced immunosuppression in Wistar rats. 62
36261807 2022
41
Computational identification and experimental validation of anti-filarial lead molecules targeting metal binding/substrate channel residues of Cu/Zn SOD1 from Wuchereria bancrofti. 62
36305196 2022
42
Bio-efficacy of Soil Actinomycetes and an Isolated Molecule 1,2-Benzenedicarboxylic Acid from Nonomuraea sp. Against Culex quinquefasciatus Say and Aedes aegypti L. Mosquitoes (Diptera: Culicidae). 62
34806140 2022
43
A call for loiasis to be added to the WHO list of neglected tropical diseases. 62
35500592 2022
44
Microfilaria in cervicovaginal Pap smears: A common parasite hiding in an unusual site: Short series of four cases with literature review. 62
36269616 2022
45
Sustainable development through the bio-fabrication of ecofriendly ZnO nanoparticles and its approaches to toxicology and environmental protection. 62
36320445 2022
46
Multi-drug resistant bacteria isolates from lymphatic filariasis patients in the Ahanta West District, Ghana. 62
36221074 2022
47
Mass drug administration for lymphatic filariasis elimination amidst COVID-19 pandemic in Odisha, India: A step towards achieving SDG-3. 62
35770893 2022
48
Prevalence, probability, and characteristics of malaria and filariasis co-infections: A systematic review and meta-analysis. 62
36269701 2022
49
Spatially Explicit Environmental Factors Associated with Lymphatic Filariasis Infection in American Samoa. 62
36288036 2022
50
Filarial thioredoxin reductase: A possible means to exterminate lymphatic filariasis. 62
36050138 2022

Variations for Filariasis

Expression for Filariasis

Search GEO for disease gene expression data for Filariasis.

Pathways for Filariasis

Pathways related to Filariasis according to GeneCards Suite gene sharing:

(show top 50) (show all 76)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 CHIT1 CTLA4 GATA3 IFNG IL10 IL2
2
Show member pathways
13.84 TLR9 TLR6 TLR4 TLR2 TLR1 PDCD1
3
Show member pathways
13.7 TNF TLR4 NOS2 IL7 IL6 IL5
4
Show member pathways
13.55 IFNG IL2 IL6 TLR1 TLR2 TLR4
5
Show member pathways
13.52 TNF TLR9 TLR6 TLR4 TLR2 TLR1
6
Show member pathways
13.4 TNF NOS2 IL7 IL6 IL5 IL2
7
Show member pathways
13.01 IL2 IL6 IL7 NOS2 TLR2 TLR4
8
Show member pathways
12.97 IL2 IL6 TLR1 TLR2 TLR4 TLR6
9
Show member pathways
12.84 IL2 IL6 TLR1 TLR2 TLR4 TLR6
10
Show member pathways
12.72 TNF TLR9 TLR6 TLR4 TLR2 TLR1
11
Show member pathways
12.72 TNF TLR9 TLR2 NOS2 IL6 EDN1
12
Show member pathways
12.7 TNF IL6 IL5 IL2 IL10 IFNG
13
Show member pathways
12.69 IFNG IL10 IL2 IL6 NOS2 TNF
14
Show member pathways
12.66 TNF TLR9 TLR6 TLR4 TLR2 TLR1
15
Show member pathways
12.51 TLR9 TLR6 TLR4 TLR2 TLR1
16
Show member pathways
12.46 TNF TLR9 TLR6 TLR4 TLR2 TLR1
17
Show member pathways
12.41 TNF TLR4 NOS2 IL6 IFNG
18
Show member pathways
12.37 TLR6 TLR4 TLR2 TLR1
19
Show member pathways
12.35 TLR9 TLR6 TLR4 TLR2 TLR1
20
Show member pathways
12.29 TNF PDCD1 IL5 IL2 IL10 IFNG
21 12.23 TNF IL6 IL10 GATA3
22 12.21 CTLA4 GATA3 IFNG IL10 IL2 PDCD1
23
Show member pathways
12.19 TLR9 TLR6 TLR4 TLR2 TLR1
24 12.19 TNF TLR9 TLR6 TLR4 TLR2 TLR1
25 12.17 TNF IL6 IL10 IFNG
26
Show member pathways
12.16 TLR9 TLR6 TLR4 TLR2 TLR1 IL5
27 12.14 TNF TLR4 NOS2 IL6 IL2 IFNG
28 12.13 TNF IL7 IL6 IL5 IL2 IL10
29 12.09 TNF NOS2 IL6 IL10 GATA3
30 12.04 CTLA4 IFNG IL10 IL2 IL5 TNF
31
Show member pathways
12 TLR9 TLR6 TLR4 TLR2 TLR1 IL6
32
Show member pathways
11.99 TLR9 TLR6 TLR4 TLR2
33 11.94 TLR4 IL6 IL2 IL10 IFNG EDN1
34 11.93 IL6 IL5 IL2 IFNG GATA3
35 11.92 TNF TLR9 IL6 IL2 IL10 IFNG
36 11.92 TNF IL7 IL5 IL2 IL10 IFNG
37
Show member pathways
11.9 GATA3 IFNG IL10 IL2 IL6 TLR1
38 11.87 IL6 IL5 IL2 IL10 IFNG EDN1
39
Show member pathways
11.85 CTLA4 GATA3 IFNG IL2 IL5 TNF
40 11.84 GATA3 IFNG IL2 IL6
41
Show member pathways
11.83 TNF NOS2 IL6 IL2 IFNG
42 11.83 TNF TLR4 PDCD1 IL6 IL2 IL10
43 11.8 TNF TLR4 IL6
44 11.79 IL5 IL10 GATA3
45 11.79 TNF IL6 IL5 EDN1
46 11.78 TNF TLR4 IL6 IL10
47 11.78 TNF TLR4 IL6 IL10
48 11.69 TNF TLR4 TLR2 NOS2 IFNG
49 11.68 TNF TLR4 IL6 IFNG
50 11.67 IFNG IL6 NOS2

GO Terms for Filariasis

Cellular components related to Filariasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.3 TNF IL7 IL6 IL5 IL2 IL10
2 extracellular region GO:0005576 10.23 ALB CHIT1 EDN1 IFNG IGHE IL10
3 Toll-like receptor 2-Toll-like receptor 6 protein complex GO:0035355 9.26 TLR6 TLR2
4 Toll-like receptor 1-Toll-like receptor 2 protein complex GO:0035354 8.92 TLR2 TLR1

Biological processes related to Filariasis according to GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.7 EDN1 GATA3 IL10 IL2 IL6 TLR2
2 signal transduction GO:0007165 10.59 TNF TLR9 TLR6 TLR4 TLR2 TLR1
3 innate immune response GO:0045087 10.58 TLR9 TLR6 TLR4 TLR2 TLR1 IGHE
4 positive regulation of gene expression GO:0010628 10.49 TNF TLR9 TLR6 TLR4 TLR2 IL7
5 inflammatory response GO:0006954 10.45 TNF TLR9 TLR6 TLR4 TLR2 TLR1
6 defense response to bacterium GO:0042742 10.41 IGHE IL10 NOS2 TLR4 TLR6 TLR9
7 cellular response to lipopolysaccharide GO:0071222 10.39 TNF TLR9 TLR4 NOS2 IL6 IL10
8 positive regulation of DNA-binding transcription factor activity GO:0051091 10.38 EDN1 IL10 IL5 IL6 TNF
9 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.37 IL6 TLR2 TLR4 TLR6 TLR9 TNF
10 cellular response to type II interferon GO:0071346 10.35 TNF TLR4 TLR2 NOS2 EDN1
11 positive regulation of inflammatory response GO:0050729 10.35 IFNG IL2 TLR2 TLR4 TLR9 TNF
12 positive regulation of tumor necrosis factor production GO:0032760 10.34 TLR9 TLR4 TLR2 TLR1 IL6 IFNG
13 defense response to Gram-negative bacterium GO:0050829 10.33 TLR9 TLR4 NOS2 IL6
14 positive regulation of type II interferon production GO:0032729 10.31 TNF TLR9 TLR4 IL2
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 10.31 TNF IL6 IL2 IFNG
16 positive regulation of NIK/NF-kappaB signaling GO:1901224 10.31 TNF TLR9 TLR4 TLR2 EDN1
17 negative regulation of interleukin-6 production GO:0032715 10.3 IL10 TLR4 TLR9 TNF
18 positive regulation of interleukin-1 beta production GO:0032731 10.3 TNF TLR6 TLR4 IL6 IFNG
19 response to virus GO:0009615 10.29 TNF TLR9 IFNG GATA3
20 positive regulation of smooth muscle cell proliferation GO:0048661 10.29 EDN1 IL6 TLR4 TNF
21 regulation of insulin secretion GO:0050796 10.28 TNF NOS2 IL6 IFNG
22 response to activity GO:0014823 10.28 TNF IL6 IL10 EDN1
23 positive regulation of interleukin-12 production GO:0032735 10.27 TLR9 TLR4 TLR2 IFNG
24 positive regulation of JUN kinase activity GO:0043507 10.27 TNF TLR9 TLR6 EDN1
25 positive regulation of interleukin-10 production GO:0032733 10.27 IL6 TLR2 TLR4 TLR9
26 response to lipopolysaccharide GO:0032496 10.27 EDN1 IL10 NOS2 TLR2 TLR4 TNF
27 positive regulation of B cell proliferation GO:0030890 10.27 TLR9 TLR4 IL7 IL5 IL2
28 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.26 IL10 IL5 IL6 TNF
29 humoral immune response GO:0006959 10.26 TNF PDCD1 IL7 IL6 IFNG GATA3
30 I-kappaB kinase/NF-kappaB signaling GO:0007249 10.25 EDN1 TLR4 TLR9 TNF
31 positive regulation of nitric oxide biosynthetic process GO:0045429 10.24 EDN1 IFNG TLR4 TLR6 TNF
32 positive regulation of vascular associated smooth muscle cell proliferation GO:1904707 10.23 TNF IL10 EDN1
33 cellular response to amyloid-beta GO:1904646 10.23 TNF TLR6 TLR4
34 negative regulation of type II interferon production GO:0032689 10.23 TLR4 IL10 GATA3
35 response to bacterium GO:0009617 10.23 TNF TLR4 NOS2 CHIT1
36 positive regulation of interferon-beta production GO:0032728 10.23 TLR2 TLR4 TLR9
37 lipopolysaccharide-mediated signaling pathway GO:0031663 10.23 TNF TLR4 TLR2
38 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.23 IL6 TLR4 TLR6 TNF
39 liver regeneration GO:0097421 10.22 TNF IL6 IL10
40 positive regulation of cytokine production GO:0001819 10.22 TNF TLR9 IL10 IFNG GATA3
41 negative regulation of interleukin-8 production GO:0032717 10.21 TLR9 TLR6 IL10
42 positive regulation of immunoglobulin production GO:0002639 10.21 TLR9 IL6 IL5 IL2 IL10
43 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 10.19 TLR9 TLR4 TLR2 IFNG
44 positive regulation of macrophage activation GO:0043032 10.18 IL10 TLR4 TLR6
45 positive regulation of MHC class II biosynthetic process GO:0045348 10.18 TLR4 IL10 IFNG
46 I-kappaB phosphorylation GO:0007252 10.17 TLR9 TLR4 TLR2
47 positive regulation of signaling receptor activity GO:2000273 10.16 IL10 IFNG EDN1
48 toll-like receptor signaling pathway GO:0002224 10.16 TLR1 TLR2 TLR4 TLR6 TLR9
49 positive regulation of T cell differentiation GO:0045582 10.15 IL7 IL2 GATA3
50 microglial cell activation GO:0001774 10.15 IFNG TLR2 TLR6 TLR9 TNF

Molecular functions related to Filariasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 10.07 TLR9 TLR6 TLR4 TLR2 TLR1
2 growth factor activity GO:0008083 10.02 IL7 IL6 IL5 IL2 IL10
3 interleukin-2 receptor binding GO:0005134 9.76 IL2 GATA3
4 NAD+ nucleotidase, cyclic ADP-ribose generating GO:0061809 9.76 TLR6 TLR4 TLR2 TLR1
5 lipopolysaccharide immune receptor activity GO:0001875 9.73 TLR4 TLR2
6 Toll-like receptor 2 binding GO:0035663 9.71 TLR6 TLR1
7 lipopeptide binding GO:0071723 9.65 TLR1 TLR2 TLR6
8 NAD(P)+ nucleosidase activity GO:0050135 9.56 TLR6 TLR4 TLR2 TLR1
9 cytokine activity GO:0005125 9.53 TNF IL7 IL6 IL5 IL2 IL10

Sources for Filariasis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....